Reuters  37 min ago  Comment 
A slide in biotech stocks pulled Wall Street and a measure of global equities lower on Friday despite a solid U.S. jobs report that weakened the dollar on views that the Federal Reserve will keep scaling back its stimulus.
FierceBiotech  Apr 4  Comment 
After a string of promising late-stage results, Amgen's cancer-fighting viral vaccine failed to extend patients' lives at a statistically significant rate, missing a secondary endpoint and marking the first blemish on the biotech's top cancer...
FierceBiotech  Apr 4  Comment 
After nearly 25 years at biotech GTx, CEO Mitchell Steiner has stepped down from the top spot, leaving behind a drug developer working to salvage its pipeline after a devastating late-stage setback.
DailyFinance  Apr 4  Comment 
NEW YORK, NY -- (Marketwired) -- 04/04/14 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) welcomes the month of April with a brand new state of the art production facility that is due to be fully operational sometime this month. Plandaí recently...
SeekingAlpha  Apr 4  Comment 
By Life Sciences Report: Biotech companies don't come into the world fully formed. Like most fledglings, they need guidance to grow, prosper and eventually thrive in public markets. Venture capitalist Ran Nussbaum of the Pontifax Group nurtures...
FierceBiotech  Apr 4  Comment 
Halozyme has pressed pause on a Phase II trial of its lead cancer candidate over safety concerns, news that sent the biotech's shares down 25% on Friday morning.  Apr 4  Comment 
NEW YORK (TheStreet) -- This week's Biotech Stock Mailbag opens with an email from Paul S. about Celgene : Why is Celgene down so much? This was a great stock last year but not so this year even though the news from the company has been good....  Apr 4  Comment 
Santhera to Present Financial Figures for 2013 and Outlook at Swiss Biotech Day 2014 Santhera Pharmaceuticals Holding AG / Santhera to Present Financial Figures for 2013 and Outlook at Swiss Biotech Day 2014 . Processed and transmitted by...
SeekingAlpha  Apr 3  Comment 
By Daniel Firl: What is Xencor? And where is the Value? Xencor (XNCR) President and CEO Bassil Dahiyat, PhD, spoke at the BioCentury Annual Future Leaders in the Biotech Industry Conference in New York on March 28. Dr Dahiyat updated us on...
SeekingAlpha  Apr 3  Comment 
By Lou Basenese: For months, the experts have been duking it out about whether or not the biotech sector is in a full-blown bubble. In one corner, we have the Richard Bernsteins of the world. Even though the iShares Nasdaq Biotechnology Fund (IBB)...


Related Articles


Biotechnology is the use of molecular biology and genetic engineering techniques to develop treatments for human diseases. Many leading companies from the industry originated in the late 70's from university research laboratories. In the 1980s after attracting venture investors and after listed in the US stock exchange,have then developed into a growing industry that uses research innovations to develop new agricultural products, biomedical tools, and human therapies such as monoclonal antibody for cancer. In 2006, 92% of employees in the biotechnology industry worked in companies that specialized in developing new drugs or medical devices and equipment, while 8% were employed in companies that specialized in agricultural products. [1] The large cap company in the group is Amgen, Genentech, Biogen-Idec, Genzyme. iShares Nasdaq Biotechnology (IBB) offers a low risk/reward investment vehicle for long term investors

Industry Information

Major Biotechnology Companies

ISTA Pharmaceuticals (ISTA)

Biotechnology Industry Trends & Forces

High Pipeline Risk for New Drugs

Dependence on Health Insurance/Medicare Coverage

Dependence on Governmental Regulations

High Volatility and Instability at Start-up

Litigation Risk

Market Share


  1. State Bioscience Initiatives 2008 Report, published by the Biotechnology Industry Organization

Top Ten/Twenty Best Selling Drugs 2009

M&A Biotechnology

Monoclonal Antibody Market 2009

Vaccine Market 2009

Global Monoclonal Antibodies Market Review 2008 (World Top Ten mAbs)

M&A Review: Pharmaceutical & Biotechnology Industry

Global Vaccine Market Review 2008 (World Top Ten Vaccines)

Ipilimumab (BMS) Review: A Cancer Breakthrough?

Denosumab (Prolia, Amgen) FDA Review & Approval

Companies in the Biotechnology Industry (193)

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki